A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity.

<h4>Purpose</h4>Although doxorubicin chemotherapy is commonly applied for treating different malignant tumors, cardiotoxicity induced by this chemotherapeutic agent restricts its clinical use. The use of silymarin/silibinin may mitigate the doxorubicin-induced cardiac adverse effects. For this aim, ... View More